Harmony Biosciences (HRMY) Tops Q2 EPS by 15c

Harmony Biosciences (NASDAQ: HRMY) reported Q2 EPS of $0.76, $0.15 better than the analyst estimate of $0.61. Revenue for the quarter came in at $134.2 million versus the consensus estimate of $142.02 million.

For earnings history and earnings-related data on Harmony Biosciences (HRMY) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Nike names former Pfizer CFO David Denton as new finance chief